Why the study?
What are the promising unapproved cardiovascular and noncardiovascular uses of calcium-channel blocking agents?
What are the promising unapproved cardiovascular and noncardiovascular uses of calcium-channel blocking agents?
Calcium-channel blockers show potential for various unapproved uses, but current evidence is largely anecdotal or poorly controlled, necessitating further rigorous study against conventional therapies.
Should not yet change practice for unapproved uses; leaves open need for rigorous randomized trials.
It is not surprising that calcium-channel blocking agents, which have numerous effects on various physiologic systems, have been employed for several "unapproved" uses. This manuscript reviews reports that have appeared within the last two years describing unapproved cardiovascular and noncardiovascular uses of the three available calcium-channel blocking agents. The cardiovascular uses discussed include hypertensive emergencies, pulmonary hypertension, congestive heart failure, aortic insufficiency, Raynaud's phenomenon, migraine headaches, antiplatelet effects and cardiac surgery. Areas of noncardiovascular use include muscular dystrophy, achalasia, esophageal spasm, dysmenorrhea, preterm labor, asthma, hyperuricemia, mania and depression and endocrinologic and oncologic conditions. While some of the data appear promising, other reports are conflicting and contradictory. Furthermore, because much of the information comes from poorly controlled trials or anecdotal reports, even the more promising uses must be studied further and compared with conventional therapy.
No takes yet. Share an insight, caveat, or question.
Bussey et al. (1984) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: